Initial Approach to Managing Irregular Menses

Diagnostic Evaluation

• The initial approach to managing irregular menses should begin with ruling out underlying gynecological problems including pregnancy, sexually transmitted infections, medication interactions, and pathologic uterine conditions before starting any treatment, as recommended by the American College of Obstetricians and Gynecologists 1
• Obtain a detailed history of bleeding patterns, including frequency, duration, and amount of flow, to assess menstrual irregularity 2
• Rule out pregnancy with a pregnancy test in all reproductive-age women with abnormal uterine bleeding, according to the American Heart Association 3
• Consider laboratory tests to evaluate for polycystic ovary syndrome (PCOS), which affects 10-25% of women with temporal lobe epilepsy and 4-6% of the general population, as reported by the Journal of Neurology, Neurosurgery and Psychiatry 4
• Perform a physical examination to assess for signs of hyperandrogenism (hirsutism, acne) which may indicate PCOS, as suggested by the Journal of Neurology, Neurosurgery and Psychiatry 4

Laboratory Testing

• For suspected reproductive endocrine disorders, consider the following tests between days 3-6 of the menstrual cycle: LH and FSH (LH/FSH ratio >2 suggests PCOS), prolactin (>20 μg/L is abnormal), progesterone (mid-luteal phase, <6 nmol/L indicates anovulation), testosterone (>2.5 nmol/L suggests PCOS), and glucose/insulin ratio (>4 suggests reduced insulin sensitivity), as recommended by the Journal of Neurology, Neurosurgery and Psychiatry 4

Treatment Algorithm

• For irregular bleeding patterns without heavy bleeding, NSAIDs such as mefenamic acid 500 mg three times daily for 5 days or celecoxib 200 mg daily for 5 days may be used for short-term treatment, as suggested by the Centers for Disease Control and Prevention 5 and the American College of Obstetricians and Gynecologists 1
• For heavy or prolonged bleeding, consider low-dose combined oral contraceptives for short-term treatment (10-20 days), as recommended by the Centers for Disease Control and Prevention 5 and the American College of Obstetricians and Gynecologists 1
• For women who cannot use estrogen-containing contraceptives, consider progestin-only options such as levonorgestrel 20 μg/d-releasing intrauterine device, which can reduce menstrual blood loss by 71-95%, as reported by the American Heart Association 3

Special Considerations

• Women with epilepsy have higher rates of PCOS (10-25%) and may require specialized management, as reported by the Journal of Neurology, Neurosurgery and Psychiatry 4
• Enhanced counseling about expected bleeding patterns can reduce method discontinuation when using hormonal treatments, as recommended by the Centers for Disease Control and Prevention 5

Follow-up Recommendations

• If irregular bleeding persists despite treatment and is unacceptable to the patient, consider alternative methods or referral to a specialist, as suggested by the Centers for Disease Control and Prevention 5
• Schedule appropriate follow-up to monitor response to treatment, as recommended by the American College of Obstetricians and Gynecologists 2

Important Caveats

• Combined hormonal contraceptives increase the risk of venous thromboembolism three to fourfold, as reported by the American College of Obstetricians and Gynecologists 1

Post‑D&C Bleeding Related to Oral Contraceptive Withdrawal

Hormonal Withdrawal as Primary Cause

• Withdrawal bleeding is the most likely explanation for bleeding that begins 4 days after a D&C when a high‑dose combined oral contraceptive (COC) is stopped; this reflects the expected physiologic response to abrupt estrogen‑progestin withdrawal. 6
• The mechanism involves a rapid decline in circulating estrogen and progestin, which triggers endometrial shedding in women discontinuing combined OCPs, especially high‑dose formulations. 7

Timing and Duration

• The onset of bleeding 4 days after COC discontinuation falls within the typical 2‑to‑7‑day window for withdrawal bleeding to appear. 7
• Withdrawal bleeding is usually self‑limited, lasting approximately 3‑7 days in most patients. 6

Impact of High‑Dose OCP Formulations

• High‑dose OCPs provide substantial hormonal support to the endometrium; their sudden removal produces a more pronounced withdrawal effect compared with lower‑dose regimens. 8

Diagnostic Considerations for Missed Endometrial Pathology

• Dilation and curettage has a false‑negative rate of up to 10 % for detecting endometrial cancer or complex hyperplasia; therefore, clinicians should remain vigilant for missed pathology when post‑procedural bleeding persists. 9
• If bleeding recurs after the expected withdrawal period, repeat endometrial sampling (e.g., office biopsy or hysteroscopic directed biopsy) is recommended because D&C alone has limited sensitivity. 9

Imaging Recommendations

• When bleeding continues beyond 7‑10 days, transvaginal ultrasound should be performed; an endometrial stripe thickness greater than 3‑4 mm warrants further diagnostic evaluation. 9